HIV Cure Scientific Working Group

艾滋病毒治疗科学工作组(SWG 1) 项目总结 艾滋病毒治疗科学工作组(SWG)将作为研究人员进行艾滋病毒研究的焦点 华盛顿特区的治愈研究。由NIH资助的实验室科学家、临床医生和 流行病学家，并与积极参与艾滋病毒治愈研究的社区成员合作 在外地，SWG将与更广泛的早期和新调查人员以及NIH内部人员接触 鼓励科学家在这一高度优先的领域开发新的赠款提案和出版物。 此前，艾滋病毒治疗特别工作组为成功申请建立 相信马丁·德莱尼·科拉布。在Believe搬到康奈尔大学后，艾滋病毒 CURE SWG于2019年1月重组，以进一步激励和协调DC的艾滋病毒治愈研究。 艾滋病毒治疗特别工作组将通过每月定期举行与艾滋病毒治疗有关的会议来实现其目标 研讨会，向DC地区的调查人员进行战略外联，促进与艾滋病毒治愈相关的新DC CFAR 试点奖项和国立卫生研究院赠款申请，以及鼓励和审查与艾滋病毒治疗有关的手稿。 艾滋病毒治愈工作组的具体目标是：1)促进在艾滋病毒治愈研究中的科学发现 2)刺激和支持创新、跨学科和多领域的发展 与艾滋病毒治疗有关的机构赠款申请和手稿，以及3)支持早期阶段，建立 以及艾滋病毒治疗研究中的新的和过渡的研究人员，重点是妇女和 代表不足的少数族裔。

HIV CURE SCIENTIFIC WORKING GROUP (SWG 1) PROJECT SUMMARY The HIV Cure Scientific Working Group (SWG) will serve as the focal point for investigators conducting HIV cure research in Washington, DC. Led by a core group of NIH-funded laboratory scientists, clinicians and epidemiologists, and in partnership with community members actively engaged in the HIV cure research field, the SWG will engage a wider circle of early stage and new investigators as well as intramural NIH scientists to stimulate the development of new grant proposals and publications in this high priority area. Previously, the HIV Cure SWG provided substantial support for the successful application to establish the BELIEVE Martin Delaney Collaboratory. Following the relocation of BELIEVE to Cornell University, the HIV Cure SWG was reconstituted in January 2019 to further galvanize and coordinate HIV cure research in DC. The HIV Cure SWG will achieve its objectives through regular monthly meetings, HIV cure-related seminars, strategic outreach to investigators in the DC area, promotion of new HIV cure-related DC CFAR pilot awards and NIH grant applications and encouragement and review of HIV cure-related manuscripts. The Specific Aims of the HIV Cure SWG are: 1) to promote scientific discovery in HIV cure research in Washington, DC, 2) to stimulate and support the development of innovative, trans-disciplinary and multi- institutional HIV cure-related grant applications and manuscripts, and 3) to support early stage, established and new and transitioning investigators in HIV cure research, with an emphasis on women and underrepresented minorities.